Coronavirus, digitalisation, MDR, Brexit – companies in the medical technology sector face major, capital-intensive challenges. What is key at this stage? By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector as a business development expert. Coronavirus takes its toll It is autumn and, as […]

Coronavirus, digitalisation, regulation, Brexit: What are the challenges facing the medtech sector, and why do we need a solid equity position now in particular? Dr. André Zimmermann is a partner of Tübingen-based industry investor SHS. An expert in business development, Dr. Zimmermann has superb connections to the medtech sector. With a PhD in the natural […]

Enzyme manufacturer c-LEcta is one of the fastest-growing biotech firms in Germany and an important supplier to numerous makers of coronavirus vaccines. c-LEcta products are also used by worldwide pharmaceutical firms and food corporations. In an interview, c-LEcta founder Dr. Marc Struhalla explains the role of the enzyme DENARASE® in the production of vaccines to […]

In the field of neuro-rehabilitation, for instance following a severe stroke or other neurological diseases, learning to walk again is crucially important. Robot-controlled gait trainers help the affected patient to stand and walk on his or her own again. Yet the LEXO® put into operation by the Wolletzsee rehabilitation clinic, north-east of Berlin, is no […]

The InnoHealth USA 2021 campaign is part of the ‘Research in Germany’ initiative of the German Federal Ministry of Education and Research (BMBF). The entire campaign is being carried out by the Fraunhofer-Gesellschaft. Our colleague Dr. André Zimmermann has been appointed to the jury of InnoHealth USA 2021 and will provide expert supervision and evaluation […]

After receiving EU approval for its minimally-invasive PiCSO system a few weeks ago, Belgium-based Miracor Medical SA is encouraged by the successful, fifth round of financing. The 24 million euros in capital raised will be devoted to further development and international marketing of the breakthrough PiCSO system. The US FDA recently identified PiCSO with its […]

Dr.-Ing. Hermann Monstadt, founder and driving force of our portfolio company phenox gmbh was awarded an honorary professorship by his alma mater, the Ruhr-University Bochum. With this award, the university honors his merits in the development of medical advanced technology for the treatment of ischemic and hemorrhagic strokes. Dr.-Ing. Monstadt has contributed to around 400 […]

Tech Tour ranks among the largest investor-oriented communities in Europe. Its aim is to create a network of innovative entrepreneurs, far-sighted investors and business partners from all over the world. More than 2000 high-tech firms regularly apply to participate in the programmes and events in which some 750 investors take part each year. We are […]

Migraine is one of the main causes of physical limitations. One in seven persons has experienced a migraine at some point in the past. Chronic migraine affects 5 percent of all migraine patients. With neurostimulation, Dutch-based Salvia BioElectronics B.V. is developing a promising therapeutic approach that offers many sufferers a reason to hope. SHS is […]

Effective October 1, 2020, Tübingen-based medtech investor SHS has appointed Prof. Marc O. Schurr, founder and Executive Board member of Ovesco AG, as Senior Advisor Schurr, a successful medtech entrepreneur and professor of experimental medicine and medical technology, understands what matters when it comes to clinical approvals and regulatory processes In Schurr, SHS gains a […]

Salvia BioElectronics raises EUR 26M (USD 31M) to develop innovative neurostimulation therapy for chronic migraine Series A led by new investors Panakès Partners, INKEF Capital and SHS Gesellschaft für Beteiligungsmanagement Eindhoven, the Netherlands, September 22, 2020 – Salvia BioElectronics B.V., a neurostimulation platform company targeting chronic migraine, today announced it has raised EUR 26M in […]

Our portfolio company Miracor raised 24m EUR to fund three clinical trials, totaling 750 patients, and start commercialization of its PiCSO therapy. The PiCSO therapy reduces infarct sizes and therefore mortality and hospitalization of patients suffering from ST-elevated myocardial infarction (STEMI).